Summary
Cancer cachexia is a severe, multifactorial wasting syndrome affecting most advanced cancer patients, with no approved therapies in the US or Europe and only ADLUMIZ approved in Japan, underscoring a major unmet need.
Despite the historical treatment gap, the cancer cachexia pipeline is now rapidly expanding, with multiple novel agents in clinical and preclinical development targeting diverse biological pathways.
Ponsegromab (Pfizer) is the leading late-stage candidate, a monoclonal antibody that neutralizes GDF-15–GFRAL signaling to shift metabolism from catabolic to anabolic, and has shown positive Phase II results on body weight and related outcom...
